Neuroprotection
15
4
4
8
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 15 trials
100.0%
+13.5% vs benchmark
20%
3 trials in Phase 3/4
13%
1 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (15)
Evaluation of BRUDYGLAUCO (DHA + Citicoline) in Patients With Glaucoma
Local Ischemic Postconditioning in Acute Ischemic Stroke
Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With No Reperfusion Therapy (INSIST-NRT)
Effect of Fixed Combination Citicoline Homotaurine and Pyrroloquinoline Quinone on Pattern-electroretinogram in Glaucoma
Effect of BrainPhyt, a Microalgae Based Ingredient on Cognitive Function in Healthy Older Subjects
Effectiveness and Biological Mechanism of Direct Ischemic Post-conditioning for Acute Stroke Patients Due to Large Vessel Occlusion
Normobaric Hyperoxia Combined With Endovascular Treatment for Acute Ischemic Stroke
Cerebrum and Cardiac Protection With Allopurinol in Neonates With Critical Congenital Heart Disease Requiring Cardiac Surgery With Cardiopulmonary Bypass
Treatment Duration on Normobaric Hyperoxia in Acute Ischemic Stroke
Magnesium Sulphate Neuroprotective Strategies for Preterm Deliveries
Normobaric Hyperoxia Combined With Endovascular Treatment in Acute Ischemic Stroke (OPENS-2)
Neuroprotective Effects of iTBS in PD
Regional Hypothermia in Combination With Endovascular Thrombectomy in Acute Ischemic Stroke
The Darbepoetin Alfa for Ischemic Surgical Complications (DISC) Dose Finding Trial
Oxygenation of the Cerebrum and Cooling During TAVI - Part I